New drug combo aims to revive immune response in lung cancer
NCT ID NCT06908304
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether a new drug called THIO, given before the immunotherapy cemiplimab, can help people with advanced non-small cell lung cancer who have already tried two prior treatments. About 300 participants will be randomly assigned to receive either the THIO-cemiplimab combo or standard chemotherapy. The main goal is to see if the combo helps people live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
THIO (a drug that targets telomeres) and cemiplimab (an immunotherapy)
What this could lead to
If successful, this could offer a new treatment option for people with advanced lung cancer who have stopped responding to standard therapies.
What could go wrong
This is a phase 3 trial, but the combination is still experimental. It may not improve survival or could cause side effects like immune reactions or chemotherapy-related toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centrum Medyczne Pratia
RECRUITINGPoznan, Poland
Contact
-
Chang-Gung Memorial Hospital - KaoHsiung
RECRUITINGKaohsiung City, Taiwan
Contact
-
Chang-Gung Memorial Hospital - Linko
RECRUITINGTaoyuan City, Taiwan
Contact
-
Changhua Christian Hospital (CCH)
RECRUITINGChanghua, Taiwan
Contact
-
Chung Shan Medical University Hospital (CSMUH)
RECRUITINGTaichung, Taiwan
Contact
-
Göztepe Süleyman Yalçın Şehir Hastanesi
RECRUITINGIstanbul, Turkey (Türkiye)
Contact
-
Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
RECRUITINGKaohsiung City, Taiwan
Contact
-
Liv Hospital
RECRUITINGAnkara, Turkey (Türkiye)
Contact
-
Medicalpark Hastanesi
RECRUITINGAdana, Turkey (Türkiye)
Contact
-
Oncolab S.R.L.
RECRUITINGCraiova, Romania
Contact
-
Spitalul Clinic Municipal de Urgenta Timisoara/ Clinica de Oncologie Medicala
RECRUITINGTimișoara, Romania
Contact
-
Taipei Medical University Hospital (TMUH)
RECRUITINGTaipei, Taiwan
Contact
-
Taipei Tzu Chi Hospital
RECRUITINGChiayi City, Taiwan
Contact
-
Tri-Service General Hospital
RECRUITINGTaipei, Taiwan
Contact
-
İstinye University
RECRUITINGIstanbul, Turkey (Türkiye)
Contact